[
  {
    "ts": null,
    "headline": "What Vertex Pharmaceuticals (VRTX)'s FDA Breakthrough for Povetacicept Means for Kidney Disease Pipeline",
    "summary": "Vertex Pharmaceuticals recently announced that the FDA has granted Breakthrough Therapy Designation to povetacicept for IgA nephropathy, along with key clinical advancements in its kidney disease pipeline. This regulatory milestone may help expedite the development of first-in-class therapies for serious renal disorders with limited treatment options. We'll examine how the FDA’s Breakthrough Therapy Designation for povetacicept strengthens Vertex's investment narrative in innovative kidney...",
    "url": "https://finnhub.io/api/news?id=1ab16e0e7410c255b22ccc427ef02df328233be5a6936ffe96ad4458a7481f5a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758981250,
      "headline": "What Vertex Pharmaceuticals (VRTX)'s FDA Breakthrough for Povetacicept Means for Kidney Disease Pipeline",
      "id": 136904152,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex Pharmaceuticals recently announced that the FDA has granted Breakthrough Therapy Designation to povetacicept for IgA nephropathy, along with key clinical advancements in its kidney disease pipeline. This regulatory milestone may help expedite the development of first-in-class therapies for serious renal disorders with limited treatment options. We'll examine how the FDA’s Breakthrough Therapy Designation for povetacicept strengthens Vertex's investment narrative in innovative kidney...",
      "url": "https://finnhub.io/api/news?id=1ab16e0e7410c255b22ccc427ef02df328233be5a6936ffe96ad4458a7481f5a"
    }
  }
]